ICH.pptx

Presented by :
MISS HARSHITA SINGHAI
m. Pharm sem. 2
Roll no. Y21254012
DEPARTMENT OF PHARMACEUTICAL SCIENCES
DR. HARISINGH GOUR VISHWAVIDYALAYA SAGAR (M.P.)
( A CENTRAL UNIVERSITY )
Session 2021-2022
1
ICH GUIDELINES
CONTENTS
1. Introduction
2. Objectives
3. Structure
4. ICH Guidelines
5. Quality Guidelines
6. Safety Guidelines
7. Efficacy Guidelines
8. Multidisciplinary Guidelines
9. References
2
I N T R O D U C T I O N
In 1989, Europe, Japan, and the United States began creating
plans for harmonisation. The International Conference on
Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use (ICH) was created in
April 1990.
ICH had the initial objective of coordinating the regulatory
activities of the European, Japanese and United States
regulatory bodies in consultation with the pharmaceutical trade
associations from these regions, to discuss and agree the
scientific aspects arising from product registration.
In 2015, ICH underwent several reforms and changed its name
to the International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human
Use while becoming a legal entity in Switzerland as a non-
profit association.
The aim of these reforms was to transform ICH into a truly
global initiative supported by a robust and transparent
governance structure.
• Harmonization of legislative and teachnical requirements.
• Mutual acceptance of data between Europe, Japan and US.
• To reduce cost of research work duplication.
• To reduce time frame for global marketing of newer drugs after
approval.
• To maintain and formulate guidelines on quality, safety and
efficacy based regulations for consumer and patient benefits.
S T R U C T U R E
International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use (ICH)
comprises the following bodies-
1. ICH Assembly
2. ICH Management Committee
3. MedDRA Management Committee
4. ICH Secretariat
I C H G U I D E L I N E S
ICH has developed over 45 harmonized guidelines .
The ICH Topics are divided into four major categories:
1. Quality (Q): Related to chemical and pharmaceutical Quality
Assurance .
2. Safety (S): Related to in vitro and in vivo preclinical studies .
3. Efficacy (E): Related to clinical studies in human subject.
4. Multidisciplinary topics (M): Related to cross-cutting topics
which do not fit uniquely into one of the above categories.
Q U A L I T Y G U I D E L I N E S
Harmonisation achievements in the Quality area include pivotal
milestones such as the conduct of stability studies, defining
relevant thresholds for impurities testing and a more flexible
approach to pharmaceutical quality based on Good
Manufacturing Practice (GMP) risk management.
ICH has produced a comprehensive set of safety Guidelines to
uncover potential risks like carcinogenicity, genotoxicity and
reprotoxicity. A recent breakthrough has been a non-clinical
testing strategy for assessing the QT interval prolongation
liability: the single most important cause of drug withdrawals in
recent years.
S A F E T Y G U I D E L I N E S
E F F I C A C Y G U I D E L I N E S
The work carried out by ICH under the Efficacy heading is concerned
with the design, conduct, safety and reporting of clinical trials. It
also covers novel types of medicines derived from biotechnological
processes and the use of pharmacogenetics/genomics techniques to
produce better targeted medicines.
MULTIDISCIPLINARY GUIDELINES
Those are the cross-cutting topics which do not fit uniquely into one
of the quality, safety and efficacy categories. It includes the ICH
medical terminology (MedDRA), the common technical document
(CTD) and the development of electronic standards for the transfer
of regulatory information (ESTRI).
T H E Q FA M I LY
• Q 1 – Stability Testing
• Q 2 – Analytical Validation
• Q 3 – Impurities
• Q 4 – Pharmacopoeias
• Q 5 – Biotechnological Products
• Q 6 – Specifications
• Q 7 – Good Manufacturing Practices
• Q 8 – Pharmaceutical Development
• Q 9 – Quality Risk Management
• Q 10 – Pharmaceutical Quality System
ICH GUIDELINES FOR STABILITY STUDIES
• Q1A(R2)- Stability Testing of New Drug Substances and Products
• Q1B- Stability Testing: Photostability Testing of New Drug
Substances and Products
• Q1C- Stability Testing for New Dosage Forms
• Q1D- Bracketing and Matrixing Designs for Stability Testing of
New Drug Substances and Products
• Q1E- Evaluation of Stability Data
• Q1F- Stability Data Package for Registration Applications in
Climatic Zones III & IV
PRINCIPLES OF THE GUIDELINE
1. Purpose of stability testing is to provide evidence how quality varies
with time under influence of temperature, humidity and light.
2. Establish re-test period for drug substances
RETEST PERIOD: The period after which samples of the drug
substance should be examined to ensure that the material is still in
compliance with the specification, and thus suitable for use in
manufacturing. A retest period should be proposed on the basis of
stability results and may be extended to five years (e.g., Ethambutol
2HCl, or Isoniazid) .
SHELF LIFE (EXPIRY DATE/EXPIRATION DATING PERIOD): The period
of time during which a pharmaceutical product, if stored correctly, is
expected to comply with the specification as determined by stability
studies on a number of batches of the product.
The shelf-life is used to establish the expiry date of each .
STABILITY
Stability of pharmaceutical product may be defined as the capability of
a particular formulation in a specific container/closure system to
remain within its physical, chemical, microbiological, therapeutic and
toxicological specification. Types stability studies:
1) Long term stability study
2) Intermediate stability study
3) Accelerated stability study
• Assurance to the patient • Economic considerations
• Legal requirement
Advantage
ICH.pptx
ICH GUIDELINES Q1A(R2)
STABILITY TESTING OF APIS
.
GENERAL
Information on the stability of the drug substance is an integral part of
the systematic approach to stability evaluation.
STRESS TESTING
Carried out on a single batch and it include the effect of temperature,
humidity where appropriate, oxidation and photolysis on DS.
Scope: These guidelines help to identify the likely degradation
products, to establish the degradation pathway and intrinsic stability
of the molecule.
SELECTION OF BATCHES- At least 3 primary batches of the drug
substance should be selected. The quality should be representative to
quality of material used for production scale.
.
CONTAINER CLOSURE SYSTEM- Stability study conducted on
the drug substance packed in a container closure system that is same
or simulate packaging proposed for storage and distribution.
SPECIFICATION- These guidelines states the list of test, references
to analytical procedure and proposed acceptance criteria.
STATEMENT AND LABELLING- A storage statement established
for labelling in relevant national/regional requirements based on the
stability evaluation of the drug substance.
Terms such as “ambient conditions” or “room temperature” should be
avoided.
Retest date for DS and Expiry date for DP should be displayed on the
container label if appropriate.
.
TESTING FREQUENCY
CLIMATE ZONE
ICH GUIDELINES Q1B
• To demonstrate that light exposure does not result in unacceptable
change
• Testing is carried out on a single batch
• Testing carried out on:
Drug substance
Exposed drug product outside of the immediate pack
Drug product in the immediate pack
Drug product in the marketing pack
Light sources:
Artificial daylight fluorescent lamp combining visible and
ultraviolet (UV) outputs, xenon or metal halide lamp.
Photostability Testing:
ICH GUIDELINES Q1C
• New dosage forms
• Same active substance
• Different administration route
• New specific functionality/delivery systems
• Reduced stability database
• Different dosage forms of same administration route.
Stability Testing for New Dosage Forms
ICH GUIDELINES Q1C
Only samples on the extremes of certain design factors are tested at
all time points as in a full design. Design Factors : >Strength >
Container Closure Sizes and/or Fills .
Bracketing
Matrixing
• Matrixing is t he statistical design of a stability schedule.
• Each storage condition should be treated separately under its own
matrixing design.
• At a given time point (other than the initial or final ones) not every
batch on stability needs to be tested.
• Full testing must be performed at the maximum storage period at
the time of submission
ICH GUIDELINES Q1E
Objectives of the Guideline : It describes:
 How to propose a retest period for drug substances and a shelf life for
drug products in the registration application .
 When and how a extrapolation beyond available data can be
considered.
 Stability Data Package for Registration Applications in Climatic
Zones III and IV
Objectives of the Guideline
 Application of ICH Q1A(R) in countries of Climatic zones III and IV
ICH GUIDELINES Q1F
THE S FAMILY
 S1A=Need for Carcinogenicity Studies of Pharmaceuticals
 S1B=Testing for Carcinogenicity of Pharmaceuticals
 S1C (R2)=Dose Selection for Carcinogenicity Studies of
Pharmaceutical
 S2 (R1)=Guidance on Genotoxicity Testing and Data
Interpretation for Pharmaceuticals intended for Human Use
 S3A=Note for Guidance on Toxicokinetics: The Assessment of
Systemic Exposure in Toxicity Studie
 S4=Duration of Chronic Toxicity Testing in Animals ( Rodent
and Non-Rodent Toxicity Testing) S5 (R2)
 S5A, S5B (M)=Detection of Toxicity to Reproduction for
Medicinal Products & Toxicity to Male Fertility
 S6 (R1)=Preclinical Safety Evaluation of Biotechnology-
Derived Pharmaceuticals
 S7A=Safety Pharmacology Studies for Human
Pharmaceuticals
 S7B=The Non-Clinical Evaluation of the Potential for
Delayed Ventricular Repolarization (QT Interval
Prolongation) by Human Pharmaceuticals
 S8=Immunotoxicity Studies for Human Pharmaceuticals
 S9=NonClinical Evaluation for Anticancer Pharmaceuticals
 S10=Photosafety Evaluation of Pharmaceuticals
 S11=Nonclinical Safety Testing in Support of Development
of Paediatric Medicines
THE S FAMILY
EFFICACY
The work carried out by ICH under the Efficacy
heading is concerned with the design, conduct,
safety and reporting of clinical trials. It also
covers novel types of medicines derived from
biotechnological processes and the use of
pharmacogenetics/ pharmacogenomics techniques
to produce better targeted medicines.
THE FAMILY OF EFFICACY
E1 - E2F Clinical Safety
E3 Clinical Study Reports
E4 Dose-Response Studies
E5 Ethnic Factors
E6 Good Clinical Practice
E7 - E11 Clinical Trials
E12 Clinical Evaluation by Therapeutic Category
E14 Clinical Evaluation
E15 - E16 Pharmacogenomics
Those are the cross-cutting topics which do not fit uniquely
into one of the Quality, Safety and Efficacy categories. It
includes the ICH medical terminology (MedDRA), the
Common Technical Document (CTD) and the development of
Electronic Standards for the Transfer of Regulatory
Information (ESTRI).
ICH Multidisciplinary Guidelines from M1 to M13
ICH Multidisciplinary Guidelines
• M1 MedDRA Terminology
• M2 Electronic Standards
• M3 Nonclinical Safety Studies
• M4 Common Technical Document
• M5 Data Elements and Standards for Drug Dictionaries
• M6 Gene Therapy
• M7 Mutagenic Impurities
• M8 Electronic Common Technical Document (eCTD)
• M9 Biopharmaceutics Classification System-based Biowaivers
• M10 Bioanalytical Method Validation
• M11 Clinical electronic Structured Harmonised Protocol (CeSHarP)
• M12 Drug Interaction Studies
• M13 Bioequivalence for Immediate-Release Solid Oral Dosage Forms
REFERENCES
• WWW.ICH.ORG
• https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegul
atoryInformation/Guidances/UCM073369.pdf
• http://www.authorstream.com/Presentation/amol.sabale-1563301-
ich-guidelines-stability-testing-ppt/
• https://www.slideshare.net/AmanKDhamrait/stability-studies-ich-
q1aq1e-guidelines-ppt
• https://www.gmp-compliance.org/guidelines/gmp-guideline/ich-
q1ar2-stability-testing-of-new-drugs-and-products-revised-
guideline
REFERENCES
ICH.pptx
1 von 33

Recomendados

PSUR von
PSURPSUR
PSURShitalDesale1
6.6K views18 Folien
Regulatory requirements of row countries von
Regulatory requirements of row countriesRegulatory requirements of row countries
Regulatory requirements of row countriesDivya Pushp
11.9K views25 Folien
Marketing Authorization Procedure in European Union von
Marketing Authorization Procedure in European UnionMarketing Authorization Procedure in European Union
Marketing Authorization Procedure in European UnionDoninder Hooda
8.3K views39 Folien
Bioequivalence studies von
Bioequivalence studiesBioequivalence studies
Bioequivalence studieswonderingsoul114
3.8K views26 Folien
ICH Guideline – Q9 von
ICH Guideline – Q9ICH Guideline – Q9
ICH Guideline – Q9rx_sonali
7.1K views24 Folien
Common Technical Document : A Regulatory Document von
Common Technical Document  : A Regulatory DocumentCommon Technical Document  : A Regulatory Document
Common Technical Document : A Regulatory DocumentTuracoz Skill Development Program
1.4K views9 Folien

Más contenido relacionado

Was ist angesagt?

Orange book von
Orange bookOrange book
Orange bookRucha Pathak
28.4K views42 Folien
Emea von
EmeaEmea
EmeaRanjeet Singh
12.4K views38 Folien
ICH GUIDELINES von
ICH GUIDELINESICH GUIDELINES
ICH GUIDELINESNaveen Kumar
203.1K views30 Folien
MHRA von
MHRAMHRA
MHRAMD Jahidul Islam
8.8K views28 Folien
Regulatory requirements for api registration von
Regulatory requirements for api registrationRegulatory requirements for api registration
Regulatory requirements for api registrationSiddu K M
10.5K views12 Folien
Ich guidelines Seminar ( Efficacy & Multidisciplinary) von
Ich guidelines Seminar ( Efficacy & Multidisciplinary)Ich guidelines Seminar ( Efficacy & Multidisciplinary)
Ich guidelines Seminar ( Efficacy & Multidisciplinary)VivekWagh13
879 views24 Folien

Was ist angesagt?(20)

Regulatory requirements for api registration von Siddu K M
Regulatory requirements for api registrationRegulatory requirements for api registration
Regulatory requirements for api registration
Siddu K M10.5K views
Ich guidelines Seminar ( Efficacy & Multidisciplinary) von VivekWagh13
Ich guidelines Seminar ( Efficacy & Multidisciplinary)Ich guidelines Seminar ( Efficacy & Multidisciplinary)
Ich guidelines Seminar ( Efficacy & Multidisciplinary)
VivekWagh13879 views
Stability studies of drug ICH Q1 von Manali Parab
Stability studies of drug ICH Q1 Stability studies of drug ICH Q1
Stability studies of drug ICH Q1
Manali Parab9.2K views
EUROPEAN MEDICAL AGENCY von datchayani
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCY
datchayani12.2K views
Product Lifecycle Management Part 1 - ICHQ12.pptx von GxPProfessional
Product Lifecycle Management Part 1 - ICHQ12.pptxProduct Lifecycle Management Part 1 - ICHQ12.pptx
Product Lifecycle Management Part 1 - ICHQ12.pptx
GxPProfessional413 views
1. Unit I - new drug discovery and development. von Audumbar Mali
1. Unit I - new drug discovery and development.1. Unit I - new drug discovery and development.
1. Unit I - new drug discovery and development.
Audumbar Mali23K views
Pharma regulatory affairs von Girish Swami
Pharma regulatory affairsPharma regulatory affairs
Pharma regulatory affairs
Girish Swami97K views

Similar a ICH.pptx

ICH QSEM Guidelines von
ICH QSEM GuidelinesICH QSEM Guidelines
ICH QSEM GuidelinesAshwinDigarse
21.5K views24 Folien
1.3 ICH .pdf von
1.3 ICH .pdf1.3 ICH .pdf
1.3 ICH .pdfKoriyaKrupali1
164 views85 Folien
Ich quality guidelines von
Ich quality guidelinesIch quality guidelines
Ich quality guidelinesSAMEERS17
1K views28 Folien
ICH [ Q ] Guidelines von
ICH [ Q ] GuidelinesICH [ Q ] Guidelines
ICH [ Q ] GuidelinesAbhishekPatil387
2.3K views34 Folien
ICH guidelines von
ICH  guidelinesICH  guidelines
ICH guidelinesmonika maan
589 views59 Folien
ICH- Objectives and stability guidelines von
ICH- Objectives and stability guidelinesICH- Objectives and stability guidelines
ICH- Objectives and stability guidelinesJaskiranKaur72
100 views42 Folien

Similar a ICH.pptx(20)

Ich quality guidelines von SAMEERS17
Ich quality guidelinesIch quality guidelines
Ich quality guidelines
SAMEERS171K views
ICH- Objectives and stability guidelines von JaskiranKaur72
ICH- Objectives and stability guidelinesICH- Objectives and stability guidelines
ICH- Objectives and stability guidelines
JaskiranKaur72100 views
ICH GUIDELINE SPECIFIC WITH Q SERIES von HEALY LAD
ICH GUIDELINE SPECIFIC WITH Q SERIESICH GUIDELINE SPECIFIC WITH Q SERIES
ICH GUIDELINE SPECIFIC WITH Q SERIES
HEALY LAD3.6K views

Más de HARSHITASINGHAI1

THEORY TO flame photometry - origin of spectra (2).pptx von
THEORY TO flame photometry - origin of spectra (2).pptxTHEORY TO flame photometry - origin of spectra (2).pptx
THEORY TO flame photometry - origin of spectra (2).pptxHARSHITASINGHAI1
49 views18 Folien
THERAPUTIC REGIMEN.pptx von
THERAPUTIC REGIMEN.pptxTHERAPUTIC REGIMEN.pptx
THERAPUTIC REGIMEN.pptxHARSHITASINGHAI1
89 views44 Folien
ANTIMETABOLITES & 6- THIOGUANINE.pptx von
ANTIMETABOLITES & 6- THIOGUANINE.pptxANTIMETABOLITES & 6- THIOGUANINE.pptx
ANTIMETABOLITES & 6- THIOGUANINE.pptxHARSHITASINGHAI1
61 views18 Folien
EVALUATION OF LIQUID DISINFECTANTS.pptx von
EVALUATION OF LIQUID DISINFECTANTS.pptxEVALUATION OF LIQUID DISINFECTANTS.pptx
EVALUATION OF LIQUID DISINFECTANTS.pptxHARSHITASINGHAI1
16 views25 Folien
Biogenesis of Glycosides.pptx von
Biogenesis of Glycosides.pptxBiogenesis of Glycosides.pptx
Biogenesis of Glycosides.pptxHARSHITASINGHAI1
10 views26 Folien
Implant medical devices.pptx von
Implant medical devices.pptxImplant medical devices.pptx
Implant medical devices.pptxHARSHITASINGHAI1
326 views34 Folien

Más de HARSHITASINGHAI1(7)

Último

Trustlife Türkiye - Güncel Platform Yapısı von
Trustlife Türkiye - Güncel Platform YapısıTrustlife Türkiye - Güncel Platform Yapısı
Trustlife Türkiye - Güncel Platform YapısıTrustlife
42 views2 Folien
Vyadhikshmatva.pptx 1.pptx von
Vyadhikshmatva.pptx 1.pptxVyadhikshmatva.pptx 1.pptx
Vyadhikshmatva.pptx 1.pptxAkshay Shetty
41 views29 Folien
Correct handling of laboratory Rats ppt.pptx von
Correct handling of laboratory Rats ppt.pptxCorrect handling of laboratory Rats ppt.pptx
Correct handling of laboratory Rats ppt.pptxTusharChaudhary99
11 views12 Folien
Impact of ICF on collaboration and communication von
Impact of ICF on collaboration and communicationImpact of ICF on collaboration and communication
Impact of ICF on collaboration and communicationOlaf Kraus de Camargo
18 views19 Folien
homedoctorbook-com-book- (1).pdf von
homedoctorbook-com-book- (1).pdfhomedoctorbook-com-book- (1).pdf
homedoctorbook-com-book- (1).pdffatimasahar769
8 views14 Folien
Pulmonary Embolism for Nurses.pptx von
Pulmonary Embolism for Nurses.pptxPulmonary Embolism for Nurses.pptx
Pulmonary Embolism for Nurses.pptxAsraf Hussain
35 views31 Folien

Último(20)

Trustlife Türkiye - Güncel Platform Yapısı von Trustlife
Trustlife Türkiye - Güncel Platform YapısıTrustlife Türkiye - Güncel Platform Yapısı
Trustlife Türkiye - Güncel Platform Yapısı
Trustlife42 views
Pulmonary Embolism for Nurses.pptx von Asraf Hussain
Pulmonary Embolism for Nurses.pptxPulmonary Embolism for Nurses.pptx
Pulmonary Embolism for Nurses.pptx
Asraf Hussain35 views
Myocardial Infarction Nursing.pptx von Asraf Hussain
Myocardial Infarction Nursing.pptxMyocardial Infarction Nursing.pptx
Myocardial Infarction Nursing.pptx
Asraf Hussain17 views
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx von ABG
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptxINTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
INTRODUCTION TO PHARMACEUTICAL VALIDATION SCOPE and MERITS OF VALIDATION.pptx
ABG115 views
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx von JubinNath2
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptxCMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx
CMC(CHEMISTRY,MANUFACTURING AND CONTROL).pptx
JubinNath29 views
Buccoadhesive drug delivery System.pptx von ABG
Buccoadhesive drug delivery System.pptxBuccoadhesive drug delivery System.pptx
Buccoadhesive drug delivery System.pptx
ABG111 views
Gastro-retentive drug delivery systems.pptx von ABG
Gastro-retentive drug delivery systems.pptxGastro-retentive drug delivery systems.pptx
Gastro-retentive drug delivery systems.pptx
ABG220 views
PATIENTCOUNSELLING in.pptx von skShashi1
PATIENTCOUNSELLING  in.pptxPATIENTCOUNSELLING  in.pptx
PATIENTCOUNSELLING in.pptx
skShashi129 views
Peptic ulcer.pdf von UVAS
Peptic ulcer.pdfPeptic ulcer.pdf
Peptic ulcer.pdf
UVAS15 views

ICH.pptx

  • 1. Presented by : MISS HARSHITA SINGHAI m. Pharm sem. 2 Roll no. Y21254012 DEPARTMENT OF PHARMACEUTICAL SCIENCES DR. HARISINGH GOUR VISHWAVIDYALAYA SAGAR (M.P.) ( A CENTRAL UNIVERSITY ) Session 2021-2022 1 ICH GUIDELINES
  • 2. CONTENTS 1. Introduction 2. Objectives 3. Structure 4. ICH Guidelines 5. Quality Guidelines 6. Safety Guidelines 7. Efficacy Guidelines 8. Multidisciplinary Guidelines 9. References 2
  • 3. I N T R O D U C T I O N In 1989, Europe, Japan, and the United States began creating plans for harmonisation. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) was created in April 1990. ICH had the initial objective of coordinating the regulatory activities of the European, Japanese and United States regulatory bodies in consultation with the pharmaceutical trade associations from these regions, to discuss and agree the scientific aspects arising from product registration.
  • 4. In 2015, ICH underwent several reforms and changed its name to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use while becoming a legal entity in Switzerland as a non- profit association. The aim of these reforms was to transform ICH into a truly global initiative supported by a robust and transparent governance structure.
  • 5. • Harmonization of legislative and teachnical requirements. • Mutual acceptance of data between Europe, Japan and US. • To reduce cost of research work duplication. • To reduce time frame for global marketing of newer drugs after approval. • To maintain and formulate guidelines on quality, safety and efficacy based regulations for consumer and patient benefits.
  • 6. S T R U C T U R E International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) comprises the following bodies- 1. ICH Assembly 2. ICH Management Committee 3. MedDRA Management Committee 4. ICH Secretariat
  • 7. I C H G U I D E L I N E S ICH has developed over 45 harmonized guidelines . The ICH Topics are divided into four major categories: 1. Quality (Q): Related to chemical and pharmaceutical Quality Assurance . 2. Safety (S): Related to in vitro and in vivo preclinical studies . 3. Efficacy (E): Related to clinical studies in human subject. 4. Multidisciplinary topics (M): Related to cross-cutting topics which do not fit uniquely into one of the above categories.
  • 8. Q U A L I T Y G U I D E L I N E S Harmonisation achievements in the Quality area include pivotal milestones such as the conduct of stability studies, defining relevant thresholds for impurities testing and a more flexible approach to pharmaceutical quality based on Good Manufacturing Practice (GMP) risk management.
  • 9. ICH has produced a comprehensive set of safety Guidelines to uncover potential risks like carcinogenicity, genotoxicity and reprotoxicity. A recent breakthrough has been a non-clinical testing strategy for assessing the QT interval prolongation liability: the single most important cause of drug withdrawals in recent years. S A F E T Y G U I D E L I N E S
  • 10. E F F I C A C Y G U I D E L I N E S The work carried out by ICH under the Efficacy heading is concerned with the design, conduct, safety and reporting of clinical trials. It also covers novel types of medicines derived from biotechnological processes and the use of pharmacogenetics/genomics techniques to produce better targeted medicines. MULTIDISCIPLINARY GUIDELINES Those are the cross-cutting topics which do not fit uniquely into one of the quality, safety and efficacy categories. It includes the ICH medical terminology (MedDRA), the common technical document (CTD) and the development of electronic standards for the transfer of regulatory information (ESTRI).
  • 11. T H E Q FA M I LY • Q 1 – Stability Testing • Q 2 – Analytical Validation • Q 3 – Impurities • Q 4 – Pharmacopoeias • Q 5 – Biotechnological Products • Q 6 – Specifications • Q 7 – Good Manufacturing Practices • Q 8 – Pharmaceutical Development • Q 9 – Quality Risk Management • Q 10 – Pharmaceutical Quality System
  • 12. ICH GUIDELINES FOR STABILITY STUDIES • Q1A(R2)- Stability Testing of New Drug Substances and Products • Q1B- Stability Testing: Photostability Testing of New Drug Substances and Products • Q1C- Stability Testing for New Dosage Forms • Q1D- Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products • Q1E- Evaluation of Stability Data • Q1F- Stability Data Package for Registration Applications in Climatic Zones III & IV
  • 13. PRINCIPLES OF THE GUIDELINE 1. Purpose of stability testing is to provide evidence how quality varies with time under influence of temperature, humidity and light. 2. Establish re-test period for drug substances RETEST PERIOD: The period after which samples of the drug substance should be examined to ensure that the material is still in compliance with the specification, and thus suitable for use in manufacturing. A retest period should be proposed on the basis of stability results and may be extended to five years (e.g., Ethambutol 2HCl, or Isoniazid) . SHELF LIFE (EXPIRY DATE/EXPIRATION DATING PERIOD): The period of time during which a pharmaceutical product, if stored correctly, is expected to comply with the specification as determined by stability studies on a number of batches of the product. The shelf-life is used to establish the expiry date of each .
  • 14. STABILITY Stability of pharmaceutical product may be defined as the capability of a particular formulation in a specific container/closure system to remain within its physical, chemical, microbiological, therapeutic and toxicological specification. Types stability studies: 1) Long term stability study 2) Intermediate stability study 3) Accelerated stability study • Assurance to the patient • Economic considerations • Legal requirement Advantage
  • 17. . GENERAL Information on the stability of the drug substance is an integral part of the systematic approach to stability evaluation. STRESS TESTING Carried out on a single batch and it include the effect of temperature, humidity where appropriate, oxidation and photolysis on DS. Scope: These guidelines help to identify the likely degradation products, to establish the degradation pathway and intrinsic stability of the molecule. SELECTION OF BATCHES- At least 3 primary batches of the drug substance should be selected. The quality should be representative to quality of material used for production scale.
  • 18. . CONTAINER CLOSURE SYSTEM- Stability study conducted on the drug substance packed in a container closure system that is same or simulate packaging proposed for storage and distribution. SPECIFICATION- These guidelines states the list of test, references to analytical procedure and proposed acceptance criteria. STATEMENT AND LABELLING- A storage statement established for labelling in relevant national/regional requirements based on the stability evaluation of the drug substance. Terms such as “ambient conditions” or “room temperature” should be avoided. Retest date for DS and Expiry date for DP should be displayed on the container label if appropriate.
  • 21. ICH GUIDELINES Q1B • To demonstrate that light exposure does not result in unacceptable change • Testing is carried out on a single batch • Testing carried out on: Drug substance Exposed drug product outside of the immediate pack Drug product in the immediate pack Drug product in the marketing pack Light sources: Artificial daylight fluorescent lamp combining visible and ultraviolet (UV) outputs, xenon or metal halide lamp. Photostability Testing:
  • 22. ICH GUIDELINES Q1C • New dosage forms • Same active substance • Different administration route • New specific functionality/delivery systems • Reduced stability database • Different dosage forms of same administration route. Stability Testing for New Dosage Forms
  • 23. ICH GUIDELINES Q1C Only samples on the extremes of certain design factors are tested at all time points as in a full design. Design Factors : >Strength > Container Closure Sizes and/or Fills . Bracketing
  • 24. Matrixing • Matrixing is t he statistical design of a stability schedule. • Each storage condition should be treated separately under its own matrixing design. • At a given time point (other than the initial or final ones) not every batch on stability needs to be tested. • Full testing must be performed at the maximum storage period at the time of submission
  • 25. ICH GUIDELINES Q1E Objectives of the Guideline : It describes:  How to propose a retest period for drug substances and a shelf life for drug products in the registration application .  When and how a extrapolation beyond available data can be considered.  Stability Data Package for Registration Applications in Climatic Zones III and IV Objectives of the Guideline  Application of ICH Q1A(R) in countries of Climatic zones III and IV ICH GUIDELINES Q1F
  • 26. THE S FAMILY  S1A=Need for Carcinogenicity Studies of Pharmaceuticals  S1B=Testing for Carcinogenicity of Pharmaceuticals  S1C (R2)=Dose Selection for Carcinogenicity Studies of Pharmaceutical  S2 (R1)=Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals intended for Human Use  S3A=Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studie  S4=Duration of Chronic Toxicity Testing in Animals ( Rodent and Non-Rodent Toxicity Testing) S5 (R2)  S5A, S5B (M)=Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility
  • 27.  S6 (R1)=Preclinical Safety Evaluation of Biotechnology- Derived Pharmaceuticals  S7A=Safety Pharmacology Studies for Human Pharmaceuticals  S7B=The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals  S8=Immunotoxicity Studies for Human Pharmaceuticals  S9=NonClinical Evaluation for Anticancer Pharmaceuticals  S10=Photosafety Evaluation of Pharmaceuticals  S11=Nonclinical Safety Testing in Support of Development of Paediatric Medicines THE S FAMILY
  • 28. EFFICACY The work carried out by ICH under the Efficacy heading is concerned with the design, conduct, safety and reporting of clinical trials. It also covers novel types of medicines derived from biotechnological processes and the use of pharmacogenetics/ pharmacogenomics techniques to produce better targeted medicines.
  • 29. THE FAMILY OF EFFICACY E1 - E2F Clinical Safety E3 Clinical Study Reports E4 Dose-Response Studies E5 Ethnic Factors E6 Good Clinical Practice E7 - E11 Clinical Trials E12 Clinical Evaluation by Therapeutic Category E14 Clinical Evaluation E15 - E16 Pharmacogenomics
  • 30. Those are the cross-cutting topics which do not fit uniquely into one of the Quality, Safety and Efficacy categories. It includes the ICH medical terminology (MedDRA), the Common Technical Document (CTD) and the development of Electronic Standards for the Transfer of Regulatory Information (ESTRI). ICH Multidisciplinary Guidelines from M1 to M13
  • 31. ICH Multidisciplinary Guidelines • M1 MedDRA Terminology • M2 Electronic Standards • M3 Nonclinical Safety Studies • M4 Common Technical Document • M5 Data Elements and Standards for Drug Dictionaries • M6 Gene Therapy • M7 Mutagenic Impurities • M8 Electronic Common Technical Document (eCTD) • M9 Biopharmaceutics Classification System-based Biowaivers • M10 Bioanalytical Method Validation • M11 Clinical electronic Structured Harmonised Protocol (CeSHarP) • M12 Drug Interaction Studies • M13 Bioequivalence for Immediate-Release Solid Oral Dosage Forms
  • 32. REFERENCES • WWW.ICH.ORG • https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegul atoryInformation/Guidances/UCM073369.pdf • http://www.authorstream.com/Presentation/amol.sabale-1563301- ich-guidelines-stability-testing-ppt/ • https://www.slideshare.net/AmanKDhamrait/stability-studies-ich- q1aq1e-guidelines-ppt • https://www.gmp-compliance.org/guidelines/gmp-guideline/ich- q1ar2-stability-testing-of-new-drugs-and-products-revised- guideline REFERENCES